HC Wainwright Analysts Boost Earnings Estimates for CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - HC Wainwright boosted their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.93) for the quarter, up from their prior estimate of ($1.01). HC Wainwright has a "Buy" rating and a $65.00 price target on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. HC Wainwright also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.07) EPS and FY2025 earnings at ($4.57) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the previous year, the company posted ($1.43) earnings per share. The company's quarterly revenue was up 71.6% compared to the same quarter last year.

A number of other equities research analysts also recently issued reports on the stock. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Truist Financial raised their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Trading Up 3.7%

CRSP stock traded up $1.35 during midday trading on Monday, reaching $37.66. The company had a trading volume of 890,247 shares, compared to its average volume of 1,667,036. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $67.88. The company has a market capitalization of $3.25 billion, a P/E ratio of -8.64 and a beta of 1.88. The company has a 50 day moving average of $37.57 and a two-hundred day moving average of $42.46.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after buying an additional 1,474,439 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after purchasing an additional 1,074,238 shares during the period. Capital International Investors grew its holdings in CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after purchasing an additional 816,789 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of CRISPR Therapeutics by 55.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after buying an additional 464,936 shares during the period. Finally, Norges Bank acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $17,458,000. 69.20% of the stock is owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. The trade was a 9.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John Greene bought 7,000 shares of the company's stock in a transaction on Wednesday, February 26th. The stock was bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 in the last ninety days. Insiders own 4.30% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.